Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PAK1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PAK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PAK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PAK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PAK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PAK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PAK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PAK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PAK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PAK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003051811 | Liver | Cirrhotic | intracellular steroid hormone receptor signaling pathway | 50/4634 | 116/18723 | 1.11e-05 | 1.59e-04 | 50 |
GO:19035333 | Liver | Cirrhotic | regulation of protein targeting | 38/4634 | 81/18723 | 1.20e-05 | 1.69e-04 | 38 |
GO:001604911 | Liver | Cirrhotic | cell growth | 160/4634 | 482/18723 | 1.50e-05 | 2.07e-04 | 160 |
GO:000716312 | Liver | Cirrhotic | establishment or maintenance of cell polarity | 82/4634 | 218/18723 | 1.55e-05 | 2.11e-04 | 82 |
GO:00362937 | Liver | Cirrhotic | response to decreased oxygen levels | 113/4634 | 322/18723 | 1.87e-05 | 2.52e-04 | 113 |
GO:00016667 | Liver | Cirrhotic | response to hypoxia | 108/4634 | 307/18723 | 2.51e-05 | 3.26e-04 | 108 |
GO:003286811 | Liver | Cirrhotic | response to insulin | 95/4634 | 264/18723 | 2.77e-05 | 3.54e-04 | 95 |
GO:003103212 | Liver | Cirrhotic | actomyosin structure organization | 74/4634 | 196/18723 | 3.39e-05 | 4.17e-04 | 74 |
GO:00066122 | Liver | Cirrhotic | protein targeting to membrane | 53/4634 | 131/18723 | 5.17e-05 | 5.95e-04 | 53 |
GO:000975511 | Liver | Cirrhotic | hormone-mediated signaling pathway | 71/4634 | 190/18723 | 7.09e-05 | 7.98e-04 | 71 |
GO:19054775 | Liver | Cirrhotic | positive regulation of protein localization to membrane | 44/4634 | 106/18723 | 1.07e-04 | 1.10e-03 | 44 |
GO:19000782 | Liver | Cirrhotic | positive regulation of cellular response to insulin stimulus | 15/4634 | 25/18723 | 1.88e-04 | 1.75e-03 | 15 |
GO:00107611 | Liver | Cirrhotic | fibroblast migration | 23/4634 | 47/18723 | 2.84e-04 | 2.51e-03 | 23 |
GO:004577311 | Liver | Cirrhotic | positive regulation of axon extension | 21/4634 | 42/18723 | 3.57e-04 | 3.03e-03 | 21 |
GO:003003812 | Liver | Cirrhotic | contractile actin filament bundle assembly | 42/4634 | 106/18723 | 4.99e-04 | 3.98e-03 | 42 |
GO:004314912 | Liver | Cirrhotic | stress fiber assembly | 42/4634 | 106/18723 | 4.99e-04 | 3.98e-03 | 42 |
GO:000155811 | Liver | Cirrhotic | regulation of cell growth | 132/4634 | 414/18723 | 5.53e-04 | 4.36e-03 | 132 |
GO:00107205 | Liver | Cirrhotic | positive regulation of cell development | 99/4634 | 298/18723 | 5.71e-04 | 4.46e-03 | 99 |
GO:00315326 | Liver | Cirrhotic | actin cytoskeleton reorganization | 42/4634 | 107/18723 | 6.28e-04 | 4.81e-03 | 42 |
GO:003223112 | Liver | Cirrhotic | regulation of actin filament bundle assembly | 41/4634 | 105/18723 | 8.18e-04 | 5.97e-03 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK1 | SNV | Missense_Mutation | | c.184N>A | p.Asp62Asn | p.D62N | Q13153 | protein_coding | tolerated(0.38) | benign(0.033) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PAK1 | SNV | Missense_Mutation | | c.1114G>A | p.Glu372Lys | p.E372K | Q13153 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PAK1 | SNV | Missense_Mutation | | c.229N>A | p.Leu77Ile | p.L77I | Q13153 | protein_coding | tolerated(0.41) | benign(0.236) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1593N>C | p.Met531Ile | p.M531I | Q13153 | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
PAK1 | SNV | Missense_Mutation | | c.113N>G | p.Ser38Cys | p.S38C | Q13153 | protein_coding | tolerated(0.17) | probably_damaging(0.917) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | insertion | Nonsense_Mutation | novel | c.226_227insGTGCACATGTATATATATGTATGCAAGAATTTTAATTTT | p.Ile75_Ser76insCysAlaHisValTyrIleCysMetGlnGluPheTerPhe | p.I75_S76insCAHVYICMQEF*F | Q13153 | protein_coding | | | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1532C>T | p.Ser511Leu | p.S511L | Q13153 | protein_coding | deleterious(0) | benign(0.135) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.946A>G | p.Ile316Val | p.I316V | Q13153 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.80N>A | p.Gly27Asp | p.G27D | Q13153 | protein_coding | deleterious_low_confidence(0.04) | benign(0.02) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | | c.95N>A | p.Gly32Glu | p.G32E | Q13153 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | AZD-1152-HQPA | AZD-1152-HQPA | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TOZASERTIB | TOZASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | MLN-8054 | MLN-8054 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565861 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | RG-1530 | RG-1530 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PF-562271 | PF-00562271 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TAE-684 | TAE-684 | |